Zimmer Biomet To Stop Selling CPT Hip Implant System By End Of 2024 Due To High Fracture Risks
Portfolio Pulse from Vandana Singh
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) will phase out its CPT Hip System by the end of 2024 due to high fracture risks, following an FDA warning. The system has a higher fracture rate compared to similar devices, prompting a recall and updated usage instructions.
September 18, 2024 | 7:40 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Zimmer Biomet is phasing out its CPT Hip System due to high fracture risks, following an FDA warning. This decision may impact the company's reputation and sales, as the product is being recalled and usage instructions updated.
The FDA warning and subsequent decision to phase out the CPT Hip System due to high fracture risks could negatively impact Zimmer Biomet's stock in the short term. The recall and updated instructions may affect the company's reputation and sales, leading to a potential decrease in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100